The purpose of this study was to assess the proportion of patients satisfied with their treatment after a change from a low-dose oral contraceptive (OC) to norethisterone acetate (NETA) because of inefficacy of OC on pain symptoms. To this end, prospective, self-controlled study was conducted on 153 women using OC as a treatment for endometriosis and with persistence of one or more moderate or severe pain symptoms. At baseline and during 12 months after a shift from OC to oral NETA, 2.5 mg/d, pelvic pain was measured by means of a 0- to 10-point numerical rating scale and a multidimensional categorical rating scale. Variations in health-related quality of life, psychological status, and sexual function were also evaluated with validated scales. At the end of the study period, participants indicated the degree of satisfaction with their treatment according to a 5-degree scale from very satisfied to very dissatisfied. A total of 28 women dropped out of the study, the main reason was intolerable side effects (n = 15). At 12-month assessment, 70% of participants were very satisfied or satisfied with NETA treatment (intention-to-treat analysis). Statistically significant improvements were observed in health-related quality of life, psychological status, and sexual function. At per-protocol analysis, almost half of the patients (58/125) reported suboptimal drug tolerability. However, complaints were not severe enough to cause dissatisfaction, drug discontinuation, or request for surgery. These encouraging results could be used to counsel women with symptomatic endometriosis not responding to OC and to inform their decisions on modifications of disease management.
DunselmanGAVermeulenNBeckerC; European Society of Human Reproduction and Embryology. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400–412.
4.
Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril. 2014;101(4):927–935.
5.
BedaiwyMAAllaireCAlfarajS. Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy. Fertil Steril. 2017;107(3):537–548.
6.
VercelliniPBraccoBMosconiP. Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study. Fertil Steril. 2016;105(3):734–743.e3.
7.
HannafordPCIversenLMacfarlaneTVElliottAMAngusVLeeAJ. Mortality among contraceptive pill users: cohort evidence from royal college of general practitioners’ oral contraception study. BMJ. 2010;340:c927.
8.
VesseyMYeatesDFlynnS. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception. 2010;82(3):221–229.
9.
VesseyMYeatesD. Oral contraceptive use and cancer: final report from the Oxford-family planning association contraceptive study. Contraception. 2013;88(6):678–683.
10.
VercelliniPPietropaoloGDe GiorgiOPasinRChiodiniACrosignaniPG. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. Fertil Steril. 2005;84(5):1375–1387.
11.
ChwaliszKSurreyEStanczykFZ. The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis. Reprod Sci. 2012;19(6):563–571.
12.
StrowitzkiTMarrJGerlingerCFaustmannTSeitzC. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010;25(3):633–641.
13.
MomoedaMHaradaTTerakawaN. Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol Res. 2009;35(6):1069–1076.
14.
LeeDYLeeJYSeoJWYoonBKChoiD. Gonadotropin-releasing hormone agonist with add-back treatment is as effective and tolerable as dienogest in preventing pain recurrence after laparoscopic surgery for endometriosis. Arch Gynecol Obstet. 2016;294(6):1257–1263.
15.
SeoJWLeeDYYoonBKChoiD. Effects of long-term postoperative dienogest use for treatment of endometriosis on bone mineral density. Eur J Obstet Gynecol Reprod Biol. 2017;212:9–12.
16.
VercelliniPBuggioLBerlandaNBarbaraGSomiglianaEBosariS. Estrogen-progestins and progestins for the management of endometriosis. Fertil Steril. 2016;106(7):1552–1571.e2.
17.
VercelliniPFacchinFBuggioL. Management of endometriosis: toward value-based, cost-effective, affordable care[published online October 05, 2017]. J Obstet Gynaecol Can. 2017.
18.
CasperRF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil Steril. 2017;107(3):533–536.
19.
ChapronCSouzaCBorgheseB. Oral contraceptives and endometriosis: the past use of oral contraceptives for treating severe primary dysmenorrhea is associated with endometriosis, especially deep infiltrating endometriosis. Hum Reprod. 2011;26(8):2028–2035.
20.
von ElmEAltmanDGEggerM. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296.
21.
DouglasIJLanghamJBhaskaranKBrauerRSmeethL. Orlistat and the risk of acute liver injury: self controlled case series study in UK clinical practice research datalink. BMJ. 2013;346:f1936.
22.
EskenaziBWarnerMBonsignoreLOliveDSamuelsSVercelliniP. Validation study of nonsurgical diagnosis of endometriosis. Fertil Steril. 2001;76(5):929–935.
23.
MooreJCopleySMorrisJLindsellDGoldingSKennedyS. A systematic review of the accuracy of ultrasound in the diagnosis of endometriosis. Ultrasound Obstet Gynecol. 2002;20(6):630–634.
24.
Van HolsbekeCVan CalsterBGuerrieroS. Endometriomas: their ultrasound characteristics. Ultrasound Obstet Gynecol. 2010;35(6):730–740.
25.
VercelliniPSomiglianaEConsonniDFrattaruoloMPDe GiorgiOFedeleL. Surgical versus medical treatment for endometriosis-associated severe deep dyspareunia: I. Effect on pain during intercourse and patient satisfaction. Hum Reprod. 2012;27(12):3450–3459.
26.
SavelliLManuzziLPollastriPMabroukMSeracchioliRVenturoliS. Diagnostic accuracy and potential limitations of transvaginal sonography for bladder endometriosis. Ultrasound Obstet Gynecol. 2009;34(5):595–600.
27.
PikettyMChopinNDoussetB. Preoperative work-up for patients with deeply infiltrating endometriosis: transvaginal ultrasonography must definitely be the first-line imaging examination. Hum Reprod. 2009;24(3):602–607.
28.
HudelistGEnglishJThomasAETinelliASingerCFKecksteinJ. Diagnostic accuracy of transvaginal ultrasound for non-invasive diagnosis of bowel endometriosis: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2011;37(3):257–263.
29.
VercelliniPDe GiorgiOMosconiPStellatoGVicentiniSCrosignaniPG. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril. 2002;77(1):52–61.
30.
VercelliniPSomiglianaEViganòPAbbiatiABarbaraGCrosignaniPG. Endometriosis: current therapies and new pharmacological developments. Drugs. 2009;69(6):649–675.
31.
SomiglianaEViganòPBarbaraGVercelliniP. Treatment of endometriosis-related pain: options and outcomes. Front Biosc. 2009;1:455–465.
32.
VercelliniPFedeleLPietropaoloGFrontinoGSomiglianaECrosignaniPG. Progestogens for endometriosis: forward to the past. Hum Reprod Update. 2003;9(4):387–396.
33.
VercelliniPCrosignaniPSomiglianaEViganòPFrattaruoloMPFedeleL. ‘Waiting for Godot’: a commonsense approach to the medical treatment of endometriosis. Hum Reprod. 2011;26(1):3–13.
34.
VercelliniPGiudiceLCEversJLAbraoMS. Reducing low-value care in endometriosis between limited evidence and unresolved issues: a proposal. Hum Reprod. 2015;30(9):1996–2004.
35.
VercelliniPCrosignaniPGAbbiatiASomiglianaEViganòPFedeleL. The effect of surgery for symptomatic endometriosis: the other side of the story. Hum Reprod Update. 2009;15(2):177–188.
36.
GuoSW. Recurrence of endometriosis and its control. Hum Reprod Update. 2009;15(4):441–461.
37.
Muneyyirci-DelaleOKaracanM. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int J Fertil Womens Med. 1998;43(1):24–27.
38.
Muneyyirci-DelaleOJalouSRahmanMNacharajuV. Can we decrease breakthrough bleeding in patients with endometriosis on norethindrone acetate?Int J Fertil Womens Med. 2003;48(1):32–36.
39.
FerreroSCameriniGSeracchioliRRagniNVenturiniPLRemorgidaV. Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. Hum Reprod. 2009;24(12):3033–3041.
40.
FerreroSCameriniGRagniNVenturiniPLBiscaldiERemorgidaV. Norethisterone acetate in the treatment of colorectal endometriosis: a pilot study. Hum Reprod. 2010;25(1):94–100.
41.
Muneyyirci-DelaleOAnopaJCharlesC. Medical management of recurrent endometrioma with long-term norethindrone acetate. Int J Womens Health. 2012;4:149–154.
42.
KaserDJMissmerSABerryKFLauferMR. Use of norethindrone acetate alone for postoperative suppression of endometriosis symptoms. J Pediatr Adolesc Gynecol. 2012;25(2):105–108.
43.
FerreroSRemorgidaVVenturiniPLLeone Roberti MaggioreU. Norethisterone acetate versus norethisterone acetate combined with letrozole for the treatment of ovarian endometriotic cysts: a patient preference study. Eur J Obstet Gynecol Reprod Biol. 2014;174:117–122.
44.
VercelliniPFrattaruoloMPSomiglianaE. Surgical versus low-dose progestin treatment for endometriosis-associated severe deep dyspareunia II: effect on sexual functioning, psychological status and health-related quality of life. Hum Reprod. 2013;28(5):1221–1230.
45.
VercelliniPBarbaraGSomiglianaEBianchiSAbbiatiAFedeleL. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril. 2010;93(7):2150–2161.
46.
BiberogluKOBehrmanSJ. Dosage aspects of danazol therapy in endometriosis: short-term and long-term effectiveness. Am J Obstet Gynecol. 1981;139(6):645–654.
47.
WareJEJrSherbourneCD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–483.
48.
McHorneyCAWareJEJrRaczekAE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31(3):247–263.
49.
WareJJrKosinskiMKellerSD. A 12-Item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996(3);34:220–233.
50.
GandekBWareJEAaronsonNK. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA project. International quality of life assessment. J Clin Epidemiol. 1998;51(11):1171–1118.
51.
ZigmondASSnaithRP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361–370.
52.
RosenRBrownCHeimanJ. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191–208.
53.
MestonCM. Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. J Sex Marital Ther. 2003;29(1):39–46.
54.
WiegelMMestonCRosenR. The Female Sexual Function Index (FSFI): cross-validation and development of clinical cut-off scores. J Sex Marital Ther. 2005;31(1):1–20.
55.
Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril. 1997;67(5):817–821.
56.
MorottiMRemorgidaVVenturiniPLFerreroS. Progestogen-only contraceptive pill compared with combined oral contraceptive in the treatment of pain symptoms caused by endometriosis in patients with migraine without aura. Eur J Obstet Gynecol Reprod Biol. 2014;179:63–68.
57.
MorottiMSozziFRemorgidaVVenturiniPLFerreroS. Dienogest in women with persistent endometriosis-related pelvic pain during norethisterone acetate treatment. Eur J Obstet Gynecol Reprod Biol. 2014;183:188–192.
58.
LouisTALavoriPWBailarJCIIIPolanskyM. Crossover and self-controlled designs in clinical research. In: BailarJCIIIMostellerF, eds. Medical Use of Statistics. Waltham, MA: NEJM Books; 1986:67–90.
59.
VercelliniPFrontinoGDe GiorgiOPietropaoloGPasinRCrosignaniPG. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to cyclic pill regimen. Fertil Steril. 2003;80(3):560–563.
VercelliniPSomiglianaECortinovisI. “You can’t always get what you want”: from doctrine to practicability of study designs for clinical investigation in endometriosis. BMC Womens Health. 2015;15:89.
62.
HapgoodJPAfricanderDLouwRRayRMRohwerJM. Potency of progestogens used in hormonal therapy: toward understanding differential actions. J Steroid Biochem Mol Biol. 2013;142:39–47.
63.
BerlandaNSomiglianaEViganòPVercelliniP. Safety of medical treatments for endometriosis. Expert Opin Drug Saf. 2016;15(1):21–30.
64.
GuoSWEversJL. Lack of transparency of clinical trials on endometriosis. Obstet Gynecol. 2013;121(6):1281–1290.
65.
GuoSW. An overview of the current status of clinical trials on endometriosis: issues and concerns. Fertil Steril. 2014;101(1):183–190.e4.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
